UPPSALA, SWEDEN / ACCESSWIRE / June 28, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, a leader in blood-based cancer monitoring, has signed a Master Service Agreement and the initial Work Order with a US-based biopharmaceutical company specializing in breast cancer. The agreement enables Biovica to provide TKa testing services to support the development of new therapeutic treatments through pre-clinical and clinical studies.
Under the agreement, Biovica will contribute to the development of first-in-class macromolecule inhibitor therapeutics for breast cancer, particularly for patients who no longer respond to CDK4/6 inhibitors. The services will utilize Biovica's TKa assay and expertise in interpreting TKa measurement dynamics. The initial TKa work order is valued at SEK 0.75M.
"We continue to experience strong growing demand for our Pharma Services Business. This agreement adds to our existing portfolio of 14 master service agreements with pharmaceutical and biotech companies and is an important step towards developing a Companion Diagnostic (CDx) product. Ultimately, Biovica aims to correlate TKa levels with improved treatment response and better patient outcomes," said Anders Rylander, CEO of Biovica.
Contact
Anders Rylander, CEO
Phone: +46 76 666 16 47
E-mail: anders.rylander@biovica.com
Anders Morén, CFO
Phone: +46 73 125 92 46
E-mail: anders.moren@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Attachments
Biovica signs new agreement supporting pharma development
SOURCE: Biovica International
View the original press release on accesswire.com
